CA
NZ
UK
AU
IND
US
MBX Biosciences (NASDAQ: MBX) has announced key leadership changes, appointing Steven Hoerter as CEO and John Smither as CFO. The moves reflect the company’s strategic direction as it continues to advance its pipeline in the biotechnology sector.
PLIANT THERAPEUTICS, INC. (NASDAQ: PLRX) has refreshed its board composition, adding two new directors to broaden its expertise and strengthen governance. The board now consists of nine members, reflecting a strategic decision to incorporate additional perspectives that support the company’s growth trajectory in the …
SS Innovations International, Inc. (NASDAQ: SSII) revealed that Sarah M. Romano will take on the chief financial officer position in the coming months. The announcement was made public in a press release dated July 14, 2026.
Revelation Biosciences unveiled a defensive strategy to ward off unsolicited takeover attempts. The biotech firm adopted a stockholder rights plan, commonly known as a poison pill, to deter investors from accumulating more than 10% of its outstanding common stock without board consent. The move …
Alto Neuroscience (NYSE: ANRO) completed a registered direct offering, selling 3,776,436 shares of common stock at $26.48 per share. The biotech firm secured approximately $93.9 million in net proceeds after underwriting discounts and expenses. The transaction closed on July 14, 2026, following regulatory clearance.
Apimeds Pharmaceuticals US has cleared a key hurdle in its effort to consolidate its share structure. The biopharmaceutical firm secured majority shareholder backing for a reverse stock split, a move aimed at adjusting its stock price and trading dynamics.
First Merchants Corp (NASDAQ: FRME) has filed a company update with the Securities Exchange, as required by the Securities Exchange Act of 1934. The update is part of the company's ongoing regulatory obligations. This filing is a routine submission for publicly traded companies like …
Contineum Therapeutics, Inc. (NASDAQ: CTNM) announced a refreshed corporate presentation on July 13, 2026. The filing emphasizes a shift toward digital dissemination, positioning the firm’s website as the primary channel for upcoming investor materials.
Accel Entertainment disclosed that its Compensation Committee approved a long‑term incentive plan and a short‑term incentive program on a recent date. The board’s decision follows recent leadership changes and aligns executive compensation with strategic objectives through a mix of equity and cash components.
Erasca (NASDAQ: ERAS) disclosed updated preliminary findings from its Phase 1 AURORAS-1 study evaluating ERAS-0015, a pan-RAS molecular glue designed to target RAS-mutant solid tumors. The results, announced on July 13, 2026, expand upon earlier data released in April 2026, incorporating additional patient data …
Please wait processing your request...